TY - JOUR
T1 - Spasmodic dysphonia and botulinum toxin
T2 - Experience from the largest treatment series
AU - Blitzer, A.
PY - 2010/7
Y1 - 2010/7
N2 - Spasmodic dysphonia is a focal laryngeal dystonia, with adductor, abductor, mixed, respiratory and singer's types. Our series over 24 years includes 1300 patients. 82% are of the adductor type; 63% were female; 12% had a positive family history and 82.4% had a focal distribution. All of the patients were managed with varying degrees of success with individualised dosing of botulinum neurotoxin A injected into the laryngeal musculature under EMG guidance.
AB - Spasmodic dysphonia is a focal laryngeal dystonia, with adductor, abductor, mixed, respiratory and singer's types. Our series over 24 years includes 1300 patients. 82% are of the adductor type; 63% were female; 12% had a positive family history and 82.4% had a focal distribution. All of the patients were managed with varying degrees of success with individualised dosing of botulinum neurotoxin A injected into the laryngeal musculature under EMG guidance.
UR - https://www.scopus.com/pages/publications/77953336664
U2 - 10.1111/j.1468-1331.2010.03047.x
DO - 10.1111/j.1468-1331.2010.03047.x
M3 - Article
C2 - 20590805
AN - SCOPUS:77953336664
SN - 1351-5101
VL - 17
SP - 28
EP - 30
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - SUPPL. 1
ER -